Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

linagliptin

- PMLiVE

Eli Lilly to acquire Dice Therapeutics for approximately $2.4bn

The deal marks a significant expansion to Lilly's immunology pipeline

- PMLiVE

AstraZeneca and Quell announce autoimmune disease partnership worth over $2bn

The collaboration will initially focus on developing cell therapies for type 1 diabetes and IBD

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

AstraZeneca to stop post-marketing study of Andexxa following early success

The company will now seek full approvals for the bleeding reversal agent in the US and EU

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Crick Institute announces new molecular glue discovery to treat different diseases

The £11.2m research investment includes funds from AstraZeneca and the EPSRC

- PMLiVE

AstraZeneca’s heart failure treatment recommended by NICE for expanded use

More than 550,000 patients have a confirmed heart failure diagnosis in England alone

- PMLiVE

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in US

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

Eli Lilly’s Alzheimer’s drug shown to significantly slow disease progression in phase 3 trial

Donanemab slowed the progression of early Alzheimer’s disease by 35% compared to placebo

- PMLiVE

Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links